NURIX THERAPEUTICS, INC. Payments of Debt Issuance Costs
NURIX THERAPEUTICS, INC. (NRIX) reported Payments of Debt Issuance Costs of $360.00 thousand for the 6-month period ending 2020-05-31, per its 10-Q filed 2021-07-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2021-07-13
- 2020-05-31: Payments of Debt Issuance Costs 6 month $360.00K.
| Period end | Payments of Debt Issuance Costs 6 month |
|---|---|
| 2020-05-31 | $360.00K 10-Q · filed 2021-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |